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Heat shock protein 90 (Hsp90) is a promising target for anti-tumor therapy. We previously reported the anti-tumor activity of
a novel Hsp90 inhibitor, KW-2478, in multiple myeloma (MM) as a single agent. In this study, we examined the combinational effect
of KW-2478 and bortezomib, a proteasome inhibitor, in vitro and in vivo. In vitro, KW-2478 enhanced bortezomib-induced cell
growth inhibition, both in MM cell lines and primary patient MM cells. The combination of KW-2478 and bortezomib also induced
caspase activation in MM cell lines. Interestingly, the combination synergistically enhanced the expression of Hsp70B, a homolog
of Hsp70, in human MM cells and peripheral blood mononuclear cells, indicating Hsp70B could be a surrogate biomarker for
the combination of Hsp90 and proteasome inhibitors. In vivo, the combination of KW-2478 with bortezomib showed synergistic
anti-tumor activity without signiﬁcant body weight loss in a subcutaneously inoculated human myeloma model. Furthermore,
the combination also showed synergistic reduction of tumor burden in bone marrow in an orthotopic myeloma model.
Our results strongly suggest that combination of KW-2478 with bortezomib could exhibit enhanced anti-tumor activity
against human myeloma.
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INTRODUCTION
Multiple myeloma (MM) is a plasma-cell malignancy characterized
by accumulation of malignant cells in the bone marrow and
production of a monoclonal immunoglobulin (M protein).
Treatment strategies for MM have changed substantially over
the past 10 years following the introduction of bortezomib and
the immunomodulatory drugs, thalidomide and lenalidomide.
Although these drugs have improved patient survival, the disease
is still incurable in the majority of patients. There is therefore an
unmet need for novel treatment strategies.
1–4
Bortezomib, a ﬁrst-in-class proteasome inhibitor, exerts anti-MM
effects through multiple mechanisms,
5 including apoptosis
induction though ER stress. As MM cells constantly produce
a large amount of M protein, they are susceptible to ER
stress; inhibition of the proteasome results in accumulation of
immunoglobulin-derived defective ribosomal products, namely
misfolded/unfolded proteins (UPR), and this accumulation
causes apoptosis following extensive ER stress.
6 The activity of
bortezomib may therefore be enhanced by combination with
drugs that induce misfolded/UPR accumulation.
Heat shock protein 90 (Hsp90) is a ubiquitously expressed
molecular chaperone, that facilitates the folding and stability of
numerous signaling molecules that control the growth and
survival of cancer cells.
7 Hsp90 also has a crucial role in
chaperoning immunoglobulins, including M protein. The
interruption of this chaperoning activity by the inhibition of
Hsp90 leads to accumulation of misfolded/unfolded proteins.
8
On the basis of the above scenario, Hsp90 inhibitors could be an
ideal drug to enhance the anti-myeloma activity of bortezomib.
Several preclinical studies have already reported synergistic
anti-myeloma activity with combinations of Hsp90 inhibitors
and bortezomib.
9–12 Furthermore, tanespimycin (17-AAG), a ﬁrst
generation Hsp90 inhibitor, with some limitations such as low
water solubility and hepatotoxicity, has demonstrated promising
activity against relapsed/refractory MM when combined with
bortezomib in clinical trials.
13
KW-2478 is a second generation Hsp90 inhibitor of non-natural
product that overcomes the limitations of tanespimycin described
above. Recently, we have reported the anti-tumor activity of
KW-2478 in MM cells as a single agent.
14 The purpose of the
present study is to investigate the anti-myeloma activity of the
combination of KW-2478 and bortezomib in vitro and in vivo
preclinical models.
MATERIALS AND METHODS
Reagents
KW-2478 was synthesized at Kyowa Hakko Kirin Co., Ltd. Bortezomib was
synthesized at Kyowa Hakko Kirin Co., Ltd or purchased from Millennium
Pharmaceuticals, Inc. (Cambridge, MA, USA). For in vitro use, both
compounds were dissolved in dimethyl sulfoxide and diluted in culture
medium. For in vivo use, both compounds were dissolved in saline.
MM-derived cell lines
OPM-2/GFP (green ﬂuorescent protein) cell line, OPM-2 cell line
15 stably
transfected with GFP gene, was obtained from Anticancer (San Diego,
CA, USA) and maintained in RPMI 1640 medium (Invitrogen, Carlsbad,
CA, USA) supplemented with 10 vol% heat-inactivated fetal bovine serum
(Invitrogen) and 1 vol% penicillin–streptomycin solution (Invitrogen).
NCI-H929 cell line
16 was obtained from American Type Culture
Collection (Manassas, VA, USA) and maintained in RPMI 1640 medium
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www.nature.com/bcjsupplemented with 10 vol% fetal bovine serum, 1mmol/l sodium pyruvate
(Invitrogen), 10mmol/l HEPES (Invitrogen), 4.5g/l D-glucose (Sigma-Aldrich,
St Louis, MO, USA) and 50mmol/l 2-mercaptoethanol (Invitrogen).
Measurement of cell viability and caspase-3 like activity of cell
lines
OPM-2/GFP cells were plated into 96-well V-bottom plates and treated
with KW-2478, bortezomib or their combinations. After 3h, the cells were
washed with culture medium twice, and further incubated in drug-free
medium for 21h to measure apoptosis induction or 45h to measure cell
viability. For measurement of cell viability, Cell Proliferation Reagent WST-8
reagent (Cell Counting Kit-8, Dojindo Molecular Technologies, Kumamoto,
Japan) was used.
For measurement of apoptosis induction, caspase-3 like protease
(DEVDase) activity was measured using the ﬂuorogenic substrate
acetyl-L-aspartyl-L-glutamyl-L-valyl-L-aspartic acid-7-amino-4-methylcoumarin
(DEVD-AMC, Peptide Institute, Osaka, Japan), as described previously.
17
Determination of synergism by the combination index (CI) method
The interaction of KW-2478 and bortezomib was determined by CI
methods using the CompuSyn software program (ComboSyn Inc.,
Paramus, NJ, USA) to determine whether the combination was additive
or synergistic. Data from cell viability assays were expressed as the fraction
of antiproliferative activity (cell viability loss) by the individual drugs or
the combination in drug-treated cells, and CI values between two drugs
were generated. A CI of 1 indicates an additive effect, whereas a CI of
o1 indicates synergy. A CI value at 50% effect (Fa¼0.5) based on the CI
isobologram equation was also calculated.
18
Measurement of drug activity in primary MM cells
Bone marrow aspirates were obtained at relapse from MM patients
following written informed consent and with the approval of the local
research ethics committee. MM cells were enriched for the plasma-cell
fraction by negative selection using the RosetteSep human MM cell
enrichment cocktail (StemCell Technologies, Grenoble, France) and Ficoll-
Hypaque (Nycomed, Oslo, Norway) density-gradient centrifugation.
Separated MM cells collected from the plasma/Ficoll interface were
washed in PBS and cryopreserved in 50% FCS, 40% RPMI, 10% dimethyl
sulfoxide in liquid nitrogen for subsequent use.
The activity of KW-2478 and bortezomib alone, and in combination, was
studied in 10 primary MM samples using HS-5 cells (ATCC) as the stromal
component in a co-culture system.
19 HS-5 cells (2.5 10
4cells/ml) in
serum-free DMEM (ATCC) were allowed to adhere overnight at 371C
before the addition of primary MM cells at a concentration of 1 10
5cells/
ml in standard RPMI 1640 medium (Sigma Aldrich Co., Gillingham, Dorset,
UK). Plates were incubated at 371C for a further 2h to allow for stromal/
MM cell interaction, before the addition of study drugs. After a 48h
incubation 100ml of cell suspension (containing the MM cells) was
removed for the determination of cell viability using the Guava Via Count
assay (Guava Technologies, Inc., Hayward, CA, USA).
Detection of apoptosis and UPR-associated proteins
Cultured cells. OPM-2/GFP and NCI-H929 cells were plated into 6-well
plates and treated with KW-2478, bortezomib or combinations of both.
After 3h the cells were washed twice with PBS and further incubated in
drug-free medium for 21h. After the total of 24h incubation, cells were
lysed with NP40 cell lysis buffer (Invitrogen) containing 1mmol/l phenyl-
methanesulfonyl ﬂuoride and 1 vol% protease inhibitor cocktail (Sigma
Aldrich). Proteins from each cell lysate were separated by SDS–PAGE,
transferred to polyvinylidene ﬂuoride membranes and immuno-blotted
with primary antibodies to Caspase-2 (Cat#551093, Becton, Dickinson and
Company, Franklin Lakes, NJ, USA), Caspase-9 (Cat#M054-3, Medical and
Biological Laboratories, Nagoya, Japan), Cleaved Caspase-3 (Cat#9661s,
Cell Signaling Technology, Danvers, MA, USA), PARP (Cat#4338-MC-50,
Travigen, Gaithersburg, MD, USA), Noxa (Cat#sc-56169, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), Hsp70 (Cat#SPA-810, Stressgen
Bioreagents, Farmingdale, NY, USA), Hsp27 (Cat#2402, Cell Signaling
Technology), Grp78 (Cat#610978, Becton, Dickinson and Company),
CHOP (Cat#2895s, Cell Signaling Technology) or b-actin (Cat#A5441, Sigma
Aldrich). The bands were detected using appropriate secondary antibodies
(horseradish peroxidase-linked anti-mouse antibody (GE Healthcare UK
Ltd, Buckinghamshire, England) or anti-rabbit antibody (GE Healthcare))
and Super Signal West Pico Chemiluminescent Substrate (Thermo Fisher
Scientiﬁc, Rockford, IL, USA).
Human peripheral blood mononuclear cells (hPBMCs). Peripheral bloods
were obtained from three healthy volunteers following written informed
consent. The hPBMCs were separated by Ficoll-Paque PLUS (GE Healthcare)
density centrifugation. Three million hPBMCs suspended in 1ml of the
assay medium (RPMI 1640 medium supplemented with 10 vol% fetal
bovine serum and 1 vol% penicillin–streptomycin solution) were plated
into 24-well plates, and treated with KW-2478, bortezomib or combina-
tions. After 3h, the cells were washed twice with PBS, and further
incubated in drug-free medium for 3h. After the total of 6h incubation
period, the cells were lysed with NP40 cell lysis buffer (Invitrogen)
containing 1mmol/l phenylmethanesulfonyl ﬂuoride and 1 vol% protease
inhibitor cocktail. Detection of apoptosis related proteins, Hsp70, Hsp70B
and Hsp27 in each cell lysate was performed as described above.
Anti-tumor activity in NCI-H929 subcutaneous model
Details of establishing the NCI-H929 s.c. bearing severe combined
immunodeﬁcient mice model were described previously.
14 Mice bearing
s.c. NCI-H929 tumors ranging from 153.74 to 294.03mm
3 were randomly
assigned into cohorts of ﬁve mice each. The treatments for each group were
as follows; (1) No treat (control), (2) bortezomib, 1mg/kg, biw 2 (on days 0,
3, 7, 10), i.v., (3) KW-2478, 50mg/kg, biw 2 (on day 0, 3, 7, 10), i.v., and (4)
KW-2478, 50mg/kg, biw þ bortezomib, 1mg/kg, biw 2. Body weight and
t u m o rv o l u m eo fm i c ew e r em e a s u r e da tl e a s tt w i c eaw e e k .T u m o rv o l u m e
was calculated by the following formula: Tumor volume¼DL DS DS 1/2
(DL, long diameter; DS, short diameter). Relative tumor volume was
represented by a V/V0 value (V0, initial tumor volume; V, tumor volume
after dosing). The relative V/V0 values on each day were converted to a
T/C value (C is V/V0 of control mouse; T is V/V0 of treated mouse).
Fourteen days after the initial administration (on day 14), blood samples
were obtained from each mouse followed by measurement of serum M
protein (Igk chain) with Human Kappa ELISA Quantization Kit (Bethyl
Laboratories, Montgomery, TX, USA).
Anti-tumor activity in OPM-2/GFP orthotopic model
Details of establishing the OPM-2/GFP orthotopic model were described
previously.
14 The day when OPM-2/GFP cells were i.v. inoculated was
designated as day 0. On day 26, serum M protein (Igl chain) of each
mouse was measured using the Human Lambda ELISA Quantitation Kit
(Bethyl Laboratories). Mice with serum M protein concentrations on
day 26 ranging from 162 to 523ng/ml were divided into 6 groups
(n¼5 in each group) on day 27 so that the mean serum M protein
concentrations in each group were similar. The treatments for each group
were as follows; (1) Saline (control), (2) KW-2478, 100mg/kg, biw 2
(on day 27, 30, 34, 37), i.v., (3) KW-2478, 200mg/kg, biw 2 (on day 27, 30,
34, 37), i.v., (4) bortezomib, 0.3mg/kg, biw 2 (on Days 27, 30, 34, 37),
i.v., (5) KW-2478, 100mg/kgþbortezomib, 0.3mg/kg, and (6) KW-2478,
200mg/kgþbortezomib, 0.3mg/kg. On day 40, serum M protein concen-
trations were measured as described above. On day 50, the GFP ﬂuores-
cence in the tumor bearing mice was measured using the AQUACOSMOS/
Macro Fluorescence System (Hamamatsu Photonics, Shizuoka, Japan).
To conﬁrm that the ﬂuorescence represented tumor burden, limbs with
ﬂuorescence from some animals were formalin ﬁxed, and the parafﬁn sections
were hematoxylin and eosin stained and histochemically examined.
Statistical methods for analysis of raw data
Tumor volume. The interaction between KW-2478 and bortezomib with
regard to anti-tumor activity was evaluated using the fractional product
method that allows an evaluation of potential synergy at a deﬁned level of
effect. In the fractional product method, the effect of two independently
acting agents is deﬁned as the product of the unaffected fractions after
treatment with either drug alone: fu (1,2)¼fu (1)  fu (2).
20 This formula
allows the predicted effect of co-administration to be calculated on the basis
of the assumption that the two agents do not interact or cooperate in
inducing their effects. If the T/C value after combined administration with KW-
2478 and bortezomib is below the calculated product, T/C combination¼T/C
KW-2478  T/C bortezomib, then the two drugs show synergy.
Statistical analysis was performed using the SAS software program (Release
9.1.3, SAS Institute Inc., Cary, NC, USA), in which the tumor volume on each
day was used as a parameter. Bartlett’s test was used to test if the samples
have equal variances. When the variance was equal (P40.05), analysis of
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test, and subsequently signiﬁcant differences between selected two groups
were analyzed by Tukey test. When the variance was not equal, analysis of
variance among each group was analyzed by Kruskal–Wallis test, and
subsequently signiﬁcant differences between selected two groups were
analyzed by Steel–Dwass test. In these tests, Po0.05 was considered
signiﬁcant.
Serum M protein. The mean and standard deviation (s.d.) of each group
were calculated. Statistical analysis was performed using the SAS software
program (Release 9.1.3, SAS Institute Inc.). Analysis of variance among
each group was analyzed by one-way analysis of variance test, and
subsequently signiﬁcant differences between selected two groups were
analyzed by Tukey’s test. In this test, Po0.05 was considered signiﬁcant.
RESULTS
Apoptosis induced by bortezomib combined with KW-2478 in MM
cell lines
First, we examined cell-killing activity of KW-2478, bortezomib,
or the combination of both, against a MM cell line, OPM-2/GFP.
OPM-2/GFP cell has an activating mutation in the FGFR3 locus
and we have previously reported that KW-2478 cytoxicity in these
cells is associated with depletion of FGFR3 with 72h continuous
exposure.
14 We are now examining the anti-tumor activity of
KW-2478 in combination with bortezomib in a clinical trial in
which both agents are administered in an intermittent schedule.
In the present study we have therefore adopted a pulsed
exposure, with a duration of 3h, as HSP90 inhibitory concen-
trations of KW-2478 are achieved for 3h after dose in MM patients
based on data from PK studies (data not shown). As shown in
Figure 1a, although KW-2478 alone had little effect on cell viability
with 3h treatment followed by a wash-out period, it potentiated
the cell-killing activity of bortezomib in a concentration depen-
dent manner. Using the fraction of antiproliferative activity
(Fraction affected, Fa), the combinatorial effect of KW-2478 with
Figure 1. Combinatorial effect of KW-2478 (KW) and bortezomib
(BTZ) on proliferation and apoptosis of OPM-2/GFP cells. (a) OPM-2/
GFP cells were treated with KW, BTZ, or their combinations for 3h,
and further incubated in drug-free medium for 45h, followed by
determination of cell viability. The results are represented as percent
of cell viability in drug-treated cells relative to untreated control
cells. Each column represents the meanþs.d. of three independent
experiments. (b) Combinatorial effect of KW-2478 and bortezomib
on CI plot in OPM-2/GFP cells. CI deﬁning the interaction between
KW-2478 and botezomib are plotted against the fraction of
antiproliferative activity. CI values: 1, additive; o1, synergistic.
(c) OPM-2/GFP cells were treated with KW, BTZ alone, or their
combinations for 3h, and further incubated in drug-free medium
for 21h, followed by measuring the cacpase-3 like proteinase
(DEVDase) activity. Data represent the meanþs.d. of three
independent experiments.
Figure 2. Apoptosis and UPR-associated proteins induced by
KW-2478 and bortezomib (BTZ) in MM cell lines. (a) OPM-2/GFP
cells were treated with KW-2478, (BTZ) alone, or their combinations
for 3h, and further incubated in drug-free medium for 21h, followed
by western blotting. (b) NCI-H929 cells were examined as described
in (a).
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trations, with a synergistic effect observed at the three highest
concentration. The addition of KW-2478 (at 2.2 to 5mmol/l) to
bortezomib (at 0.022 to 0.05mmol/l) showed CI values of 0.76 to
0.82, suggesting that this combination was synergistic across a
wide range of concentrations (Figure 1b).
Effect of KW-2478 on apoptosis induction, indicated as DEVDase
activity, by bortezomib was also examined in OPM-2/GFP cells.
Although KW-2478 alone induced little caspase activation, the
addition of 0.44 to 3.3mmol/l KW-2478 enhanced caspase
activation by bortezomib at concentrations ranging from 0.01 to
0.05mmol/l (Figure 1c). Apoptosis induction by the combination of
KW-2478 and bortezomib was conﬁrmed by caspase-2, 3, 9 and
PARP cleavage (caspase-2 and -9 represent the uncleaved forms,
with reductions in band intensity indicating cleavage (Figure 2a)).
Apoptosis induction, indicated as caspase-3, 9 and PARP cleavage,
was also seen in NCI-H929 cells (Figure 2b).
It has been reported that Noxa, a BH3-only member of the
Bcl-2 family, is a mediator of apoptosis after exposure to
bortezomib.
21–23 Consistent with these reports, the expression of
Noxa was induced by bortezomib in OPM-2/GFP cells (Figure 2a).
While KW-2478 alone had little effect on Noxa expression, the
addition of KW-2478 to bortezomib resulted in a further increase
in Noxa compared with bortezomib alone. This data suggest that
KW-2478 enhanced apoptosis by increasing Noxa induction in
OPM-2/GFP cells. In NCI-H929 cells Noxa levels remained very low.
UPR-associated proteins induced by KW-2478 and bortezomib in
MM cell lines
As it is well established that Hsp90 inhibition results in increased
Hsp70 expression, an effect often used as a surrogate marker of
Figure 3. Cytotoxicity in MM patient samples. The effect of single
agent KW-2478 (KW) (K), bortezomib (BTZ) (J) and combinations
of both (K) on the viability of primary MM in co-culture (*Po0.05,
**Po0.01 vs the same concentration of bortezomib alone by paired
t-test). NS, not signiﬁcant.
Figure 4. Hsps induced by KW-2478 (KW) and bortezomib (BTZ) in hPBMCs. hPBMCs were treated with KW-2478, BTZ alone, or their
combinations for 3h, and further incubated in drug-free medium for 3h, followed by western blotting.
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an Hsp70 homolog, in treated cells. As shown in Figure 2, KW-2478
treatment increased the level of Hsp70, as expected, and this
effect was enhanced by the addition of bortezomib in both
OPM-2/GFP and NCI-H929 cell lines. To our surprise, although we
could not detect Hsp70B in NCI-H929 cells, a marked induction
in Hsp70B was found only in the combination of KW-2478 and
bortezomib in OPM-2/GFP (Figure 2a). This ﬁnding indicates that
induction of Hsp70B, a secondary responder to proteotoxic stress,
could be a surrogate biomarker speciﬁc to the combination of
KW-2478 and bortezomib, as little or no basal expression was
observed in untreated cells.
24 As an increase in the expression of
the ER-associated chaperone, Grp78, (also known as BiP), has been
associated with bortezomib-induced apoptosis in MM cell lines,
25,26
we investigated its induction in both cell lines. No change in Grp78
was observed in OPM-2/GFP cells (Figure 2a). In NCI-H929 cells,
bortezomib induced Grp78 at all concentrations, but KW-2478 had
little or no effect on Grp78 expression levels (Figure 2b).
Cytotoxicity in MM patient samples
Anti-MM activity of the combination of KW-2478 and bortezomib
against 10 different primary MM samples was evaluated in the
HS-5 co-culture system (Figure 3). As with the cell line data
reported in Figure 1a, minimally toxic concentrations of KW-2478
(1 and 2mmol/l) increased the activity of bortezomib, an effect
that was statistically signiﬁcant in three of the four combinations
studied. It is noteworthy that not all primary samples showed
an increased effect with the combination, an observation most
apparent in several samples at 3nmol/l bortezomib.
Hsp70B as a possible surrogate biomarker of KW-2478 and
bortezomib combination
To verify if Hsp70B induction might be useful as a surrogate
biomarker of the combination therapy, we examined Hsp70B
induction using hPBMCs from healthy donors. As shown in
Figure 4, bortezomib alone had no effect on Hsp70B at any
concentration studied. Although KW-2478 alone induced Hsp70 in
all three samples, and Hsp27 in two of the three, KW-2478 alone
had only a small effect on Hsp70B in two samples. However,
signiﬁcant induction of Hsp70B was observed when KW-2478 and
bortezomib were combined, particularly at higher concentrations
of KW-2478. This provides further evidence that Hsp70B may be
useful as a surrogate biomarker speciﬁc to the combination of
bortezomib and KW-2478.
KW-2478 enhanced anti-tumor activity of bortezomib in s.c.
xenograft model
We next investigated in vivo anti-tumor activity in an NCI-H929 s.c.
xenograft model using a twice-weekly administration schedule
for 2 weeks. Although KW-2478 or bortezomib alone showed
moderate anti-tumor effects, activity was clearly more marked
when the two agents were combined (Figure 5a). The differences
between each single agent (KW-2478 or bortezomib) and the
combination group were statistically signiﬁcant on day 14. The
observed T/C values in the combination group were smaller than
calculated T/C values based on the T/C values for each agent
alone, conﬁrming a synergistic interaction (Table 1).
The increased activity of the combination was further conﬁrmed
by the change in serum M protein, which was signiﬁcantly lower in
mice treated with KW-2478 and bortezomib in combination than
in mice receiving either agent alone as monotherapy (Figure 5b).
Importantly, no additional toxicity was observed in the combina-
tion group as assessed by treatment-related mortality and body
weight change (data not shown).
KW-2478 enhanced anti-tumor activity of bortezomib in
orthotopic xenograft model
In order to investigate the anti-tumor effect of KW-2478 and
bortezomib in a more clinically relevant model, we used an
i.v. inoculated OPM-2/GFP model, which we have described
previously.
14 Figure 6a shows typical observations in this model.
Thirty-three days after OPM-2/GFP cell inoculation, GFP signal was
Figure 5. Anti-tumor activity in NCI-H929 s.c. xenograft model.
(a) NCI-H929 cells (1 10
7cells/mouse) were inoculated s.c. into
the ﬂank of severe combined immunodeﬁcient mice. After 10 days,
KW-2478 (KW) or/and bortezomib (BTZ) were administered i.v. twice
weekly for 2 weeks. Each plot represents the meanþs.d. of tumor
volume (n¼5). *Po0.05; Steel–Dwass test. (b) Fourteen days after
the initial administration, serum M protein concentrations were
measured. Each bar represents the meanþs.d. (n¼5), *Po0.05;
Tukey’s test.
Table 1. T/C values in Figure 5a
Treatment Day 0 Day 4 Day 7 Day 10 Day 14 Day 17 Day 21
No treat (control) 1.000 1.000 1.000 1.000 1.000 1.000 1.000
BTZ 1mg/kg biw 2 1.000 0.775 0.620 0.594 0.445 0.478 0.490
KW-2478 50mg/kg biw 2 1.000 0.544 0.522 0.423 0.305 0.304 0.353
KW (50, biw 2) þ BTZ 1.000 0.274 0.234 0.153 0.084 0.096 0.117
KW (50, biw 2) þ BTZ (calculated) 1.000 0.422 0.323 0.251 0.136 0.146 0.173
Abbreviations: BTZ, bortezomib; KW, KW-2478.
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examined. Inoculated OPM-2/GFP cells developed multi MM
lesions in bone marrow, resembling human MM. As shown in
Figure 6b, in KW-2478 monotherapy groups at either 100 or
200mg/kg (groups 2 and 3), no signiﬁcant decreases of GFP
ﬂuorescence intensity were seen. There was a small decrease
in GFP-ﬂuorescent lesions in the bortezomib 0.3mg/kg mono-
therapy group (group 4), compared with control animals. In the
KW-2478 and bortezomib combination groups (Groups 5 and 6),
clear decreases in GFP ﬂuorescence intensity were seen compared
with the control group, and compared with mice treated with
bortezomib or KW-2478 alone. This was also apparent in the lower
serum M protein concentrations in mice treated with KW-2478
and bortezomib in combination, compared with those in each
monotherapy group, an effect that reached statistical signiﬁcance
with the 200mg KW-2478 0.3mg bortezomib group compared
with bortezomib alone (Figure 6c). As with NCI-H929 xenograft
model, no additive toxicity was observed in the combination
group (data not shown).
DISCUSSION
Despite recent advances in treatment, MM remains an incurable
disease for the majority of patients. To improve the outcome,
Figure 6. Anti-tumor activity in OPM-2/GFP orthotopic model. OPM-2/GFP cells (1 10
7cells/mouse) were inoculated i.v. into severe
combined immunodeﬁcient (SCID) mice. (a) Thirty-three days after cell inoculation, GFP ﬂuorescence was measured followed by histochmical
examination, (b) Twenty-seven days after cell inoculation, KW-2478 (KW) or/and bortezomib (BTZ) were administered i.v. twice weekly for
2 weeks. Photographs were taken 50 days after cell inoculation from dorsal angle. (c) Forty days after cell inoculation, serum M protein
concentration was measured by ELISA. Each column represents the meanþs.d. n¼5. *Po0.05; Tukey’s test.
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appropriate anti-myeloma agents are urgently needed. In the
present study, we showed the beneﬁcial anti-tumor effects of
KW-2478 and bortezomib combination in vitro and in vivo using
MM cell lines. We could also show increased anti-MM activity
with a combination of KW-2478 and bortezomib compared with
bortezomib alone in primary MM patient samples.
Previously, it has been reported that the combination of Hsp90
inhibition and proteasome inhibition resulted in enhanced anti-
tumor activity.
8–11 The results of our current study are consistent
with those previous reports. Although the underlying mechanism
of the combinatorial effect is not fully understood, the following
mechanism has been proposed. Many cellular proteins are
targeted for degradation in the proteasome. When combined
with a proteasome inhibitor, Hsp90 inhibition can overload the
protein degradation machinery and lead to accumulation of UPR
and consequent stress response. As a result, the combined
inhibition of both proteasome and Hsp90 induces excessive UPR,
including marked induction of Grp78 (BiP) and CHOP and
resultant cell death.
8 Recently, Roue et al.
26 have reported that
resistance to bortezomib can be overcome by Hsp90 inhibition
with IPI-504, a geldanamycin analog,
26 associated with depletion
of Grp78. In our present study, however, KW-2478 induced neither
accumulation of ubiquitinated proteins nor CHOP (data not
shown). Furthermore, KW-2478 had little effect on the level of
Grp78 protein. Therefore, the underling mechanism mediating the
effects observed in our study may be different from those
reported previously. A difference between our study and previous
studies are the drug treatment regimen; we adopted 3h pulse
condition while others used continuous treatment. Mechanisms
other than Grp78 inhibition or CHOP induction may therefore be
important with pulse drug treatments.
Noxa, a BH3-only protein is considered as a key mediator
of bortezomib-induced apoptosis. In agreement with previous
reports,
21–23 Noxa was induced by exposure to bortezomib in
our present study in OPM-2/GFP cells. Noticeably, KW-2478
enhanced bortezomib dependent Noxa induction in a dose-
dependent manner. In parallel with the Noxa induction, caspase
activation and apoptosis was observed in the MM cells. Therefore,
Noxa induction could be one of the mechanisms underlying
the combinatorial effects observed. However, in NCI-H929 cells,
Noxa induction was not observed, suggesting mechanisms
other than Noxa induction also contribute to the activity of
the combination. In all the cells tested, OPM-2/GFP, NCI-H929
and hPBMCs, enhanced Hsp70 and/or Hsp70B expression was
observed with combination treatments. As Hsp70 family proteins
are known to be expressed in response to proteotoxic stress,
24,27
the extensive accumulation of proteotoxic stress is thought to be a
basis of the combinatorial effect.
The combination of KW-2478 and bortezomib synergistically
enhanced the expression of Hsp70B, a homolog of Hsp70, in not
only MM cell line but also hPBMC. Interestingly, such extensive
Hsp70B induction was only observed in the combination
treatment with both drugs. This result indicated Hsp70B could
be a surrogate biomarker to monitor the combinatorial effect.
Such a surrogate biomarker would not act as a predictive
biomarker of combination activity, but might be useful to
monitor the biological activity of the two drugs after treatment.
Speciﬁcally, if an upregulation of Hsp70B was observed in the
PBMCs of a patient after treatment, it would suggest biological
activity of the two drugs in combination, before a clinical response
was apparent. This may be useful in making decisions about
continuing treatment in an individual patient and in selecting the
appropriate dosing and administration schedule as this combina-
tion is further developed in the clinic.
The combined anti-tumor activity of KW-2478 with borte-
zomib was evaluated in a NCI-H929 s.c. inoculated model
and an OPM-2/GFP orthotopic model, using a twice-weekly
administration schedule similar to the clinical administration
schedule of bortezomib. In both models, the combination of
KW-2478 and bortezomib showed beneﬁcial activities. The
enhanced anti-tumor activity observed in the OPM-2/GFP
orthotopic model may be particularly informative, as this
model is considered to be more relevant to the pathological
condition in MM disease. These data indicate that it may be
beneﬁcial to add KW-2478 to bortezomib in a clinically practical
twice-weekly administration schedule.
The combination of another Hsp90 inhibitor, 17-AAG, and
bortezomib has already been investigated in a Phase II study,
and has demonstrated signiﬁcant and durable responses with
acceptable toxicity in patients with relapsed and refractory MM.
13
As KW-2478 has superior physicochemical and toxicological
properties to 17-AAG, the combination of KW-2478 and borte-
zomib is expected to be more promising. The Phase I/II study
of KW-2478 in combination with bortezomib is underway in
MM patients.
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